WO1996018733A3 - Inactivation induite par ribozyme de l'arn associe a la leucemie - Google Patents

Inactivation induite par ribozyme de l'arn associe a la leucemie Download PDF

Info

Publication number
WO1996018733A3
WO1996018733A3 PCT/US1995/016451 US9516451W WO9618733A3 WO 1996018733 A3 WO1996018733 A3 WO 1996018733A3 US 9516451 W US9516451 W US 9516451W WO 9618733 A3 WO9618733 A3 WO 9618733A3
Authority
WO
WIPO (PCT)
Prior art keywords
associated rna
leukemia
rna
ribozyme
mediated inactivation
Prior art date
Application number
PCT/US1995/016451
Other languages
English (en)
Other versions
WO1996018733A2 (fr
Inventor
Umberto Pace
Shaji T George
Allan R Goldberg
Original Assignee
Innovir Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovir Lab Inc filed Critical Innovir Lab Inc
Priority to AU49619/96A priority Critical patent/AU4961996A/en
Publication of WO1996018733A2 publication Critical patent/WO1996018733A2/fr
Publication of WO1996018733A3 publication Critical patent/WO1996018733A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/126—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes involving RNAse P
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3527—Other alkyl chain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/028—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a herpesvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne la construction de molécules d'ARN, y compris de ribozymes, de séquences guides externes pour la ribonucléase P et d'oligonucléotides antisens, lesquelles molécules, suivant le cas, favorisent la coupure par ribozymes d'ARN spécifiques de cancers, ou en bloquent la transcription. Ces ARN sont notamment l'ARN de la leucémie promyéloleucocytaire aiguë, l'ARN du lymphome folliculaire, et l'ARN de la leucémie myéloloïde chronique. L'invention concerne également des procédés de production et d'utilisation de telles molécules d'ARN.
PCT/US1995/016451 1994-12-14 1995-12-14 Inactivation induite par ribozyme de l'arn associe a la leucemie WO1996018733A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU49619/96A AU4961996A (en) 1994-12-14 1995-12-14 Ribozyme-mediated inactivation of leukemia-associated rna

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35495694A 1994-12-14 1994-12-14
US354,956 1994-12-14

Publications (2)

Publication Number Publication Date
WO1996018733A2 WO1996018733A2 (fr) 1996-06-20
WO1996018733A3 true WO1996018733A3 (fr) 1996-12-12

Family

ID=23395618

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/016451 WO1996018733A2 (fr) 1994-12-14 1995-12-14 Inactivation induite par ribozyme de l'arn associe a la leucemie

Country Status (2)

Country Link
AU (1) AU4961996A (fr)
WO (1) WO1996018733A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869248A (en) * 1994-03-07 1999-02-09 Yale University Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences
US5683873A (en) * 1995-01-13 1997-11-04 Innovir Laboratories, Inc. EGS-mediated inactivation of target RNA
US6057153A (en) * 1995-01-13 2000-05-02 Yale University Stabilized external guide sequences
US20020081733A1 (en) * 1995-11-14 2002-06-27 Catherine M. Verfaillie Method to prepare drug-resistant, non-malignant hematopoietic cells
US5877162A (en) * 1996-03-14 1999-03-02 Innovir Laboratories, Inc. Short external guide sequences
WO1998006837A1 (fr) * 1996-08-16 1998-02-19 Yale University Transformation du phenotype de bacteries chimio-resistantes en phenotype chimio-sensible
AU737190B2 (en) * 1996-12-06 2001-08-09 Niels Pallisgaard Detection of chromosomal abnormalities
US6013447A (en) * 1997-11-21 2000-01-11 Innovir Laboratories, Inc. Random intracellular method for obtaining optimally active nucleic acid molecules
EP1032707A2 (fr) * 1997-11-21 2000-09-06 Yale University Procede d'identification et d'inhibition de molecules fonctionnelles d'acide nucleique dans des cellules
US6248525B1 (en) 1998-03-30 2001-06-19 Yale University Method for identifying essential or functional genes
EP1860188B1 (fr) 1999-07-07 2011-05-04 ZymoGenetics, Inc. Récepteur de cytokine humain
US20030153083A1 (en) 2000-01-31 2003-08-14 Alexei Shir Selective killing of cells by activation of double-stranded rna dependent protein kniase-pkr
FR2832154B1 (fr) 2001-11-09 2007-03-16 Centre Nat Rech Scient Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
EP1356820A1 (fr) * 2002-04-26 2003-10-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Vaccin ADN combiné avec un inducteur de l'apoptose de cellules tumorales

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023057A1 (fr) * 1992-05-14 1993-11-25 Ribozyme Pharmaceuticals, Inc. Procede et reactif destines a empecher l'evolution du cancer
WO1995023225A2 (fr) * 1994-02-23 1995-08-31 Ribozyme Pharmaceuticals, Inc. Procede et reactif inhibiteur de l'expression de genes concernant une affection

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023057A1 (fr) * 1992-05-14 1993-11-25 Ribozyme Pharmaceuticals, Inc. Procede et reactif destines a empecher l'evolution du cancer
WO1995023225A2 (fr) * 1994-02-23 1995-08-31 Ribozyme Pharmaceuticals, Inc. Procede et reactif inhibiteur de l'expression de genes concernant une affection

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
37TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY, SEATTLE, WASHINGTON, USA, DECEMBER 1-5, 1995. *
85TH ANN.MEET. AM.ASSOC. CANCER RES.; SAN FRANCISCO, 10 April 1994 (1994-04-10) - 13 April 1994 (1994-04-13) *
DE THŸ, H. ET AL.: "The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promylocytic leukemia encods a functionally altered RAR", CELL, vol. 66, 23 August 1991 (1991-08-23), NA US, pages 675 - 684, XP002008608 *
KEYSTONE SYMPOSIUM ON RIBOZYMES: BASIC SCIENCE AND THERAPEUTIC APPLICATIONS, BRECKENRIDGE, COLORADO, USA, 15 January 1995 (1995-01-15) - 21 January 1995 (1995-01-21) *
NASON-BURCHENAL, K. ET AL.: "Over-expression of ribozymes cleaving PML-RAR-alpha in vitro is cytotoxic to acute promyelocytic leukemia cells in vivo.", BLOOD 86 (10 SUPPL. 1). PAGE 263A, ABSTRACT 1037, 15 November 1995 (1995-11-15), XP002008611 *
NORDSTROM, J. ET AL.: "External guide sequences that direct human ribonuclease P to cleave the fusion junction of the PML-RAR-alpha RNA of acute promyelocytic leukemia.", JOURNAL OF CELLULAR BIOCHEMISTRY SUPPLEMENT 0 (19A).1995. PAGE 223, ABSTRACT A6-317, XP002008610 *
PACE, U. ET AL.: "A ribozyme which discriminates in vitro between PML/RAR alpha, the t(15;17)-associated fusion RNA of acute promyelocytic leukemia, and PML and RAR alpha, the transcripts from the nonrearranged alleles.", CANCER RESEARCH, (1994 DEC 15) 54 (24) 6365-9., XP002008609 *
PACE, U. ET AL.: "A ribozyme which discriminates in vitro between the acute promyelocytic leukemia t(15;17) fusion RNA, PML/RAR alpha, and the normal transcripts from the non-rearranged alleles.", PROC ANNU MEET AM ASSOC CANCER RES, VOL. 35, PAGE 206, ABSTRACT #1227, March 1994 (1994-03-01), XP002008607 *
PAOLELLA, G. ET AL.: "NUCLEASE RESISTANT RIBOZYMES WITH HIGH CATALYTIC ACTIVITY", EMBO JOURNAL, vol. 11, no. 5, 1 May 1992 (1992-05-01), pages 1913 - 1919, XP000268586 *
ROSSI, J. ET AL.: "RNA ENZYMES (RIBOZYMES) AS ANTIVIRAL THERAPEUTIC AGENTS", TRENDS IN BIOTECHNOLOGY, vol. 8, no. 7, 1 July 1990 (1990-07-01), pages 179 - 183, XP000133090 *
SYMONS, R. H.: "RIBOZYMES", CURRENT OPINION IN STRUCTURAL BIOLOGY, vol. 4, no. 3, 1 June 1994 (1994-06-01), pages 322 - 330, XP000523747 *

Also Published As

Publication number Publication date
WO1996018733A2 (fr) 1996-06-20
AU4961996A (en) 1996-07-03

Similar Documents

Publication Publication Date Title
WO1996018733A3 (fr) Inactivation induite par ribozyme de l'arn associe a la leucemie
FI955428A (fi) Antisene-oligonukleotideja, jotka vastustavat poikkeavaa kietoutumista, ja menetelmiä niiden käyttämiseksi
US5246921A (en) Method for treating leukemias
WO1996018736A3 (fr) Procede et reactif servant a traiter les etats arthritiques, a introduitre une tolerance aux greffes et a inverser les reactions immunes
WO2003046173A1 (fr) Systeme d'expression d'arn si et procede de production de cellules d'inactivation de genes fonctionnelles et analogues au moyen de ce systeme
US5646031A (en) SArMV and sCYMVI hairpin ribozymes
DE60037938D1 (de) Antisense-therapie für trpm-2
AU2003293035A1 (en) Treatment of neurodegenerative disease through intracranial delivery of short interfering rna (sirna)
WO2000060115A3 (fr) Methode d'identification de sites de liaison accessibles dans l'arn
ATE342969T1 (de) Ribozyme die fähig sind die expression des ccr5 rezeptor zu hemmen
WO1996021731A3 (fr) Sequences guides externes stabilisees
WO1996019568A3 (fr) Analogues de ribozymes stabilises
EP1007655A4 (fr) Activateurs de rnase l et oligonucleotides antisens efficaces dans le traitement des infections a rsv
AU637354B2 (en) Genetic units for inhibiting the function of rna
WO2003056022A3 (fr) Organisme transgenique
IL161664A0 (en) METHOD FOR THE IN VITRO SYNTHESIS OF SHORT DOUBLE STRANDED RNAs
WO2003046186A8 (fr) Systeme d'expression d'arnsi et procede de production de cellule knockdown a gene fonctionnel ou analogue utilisant ce systeme
AU4595399A (en) Antisense oligonucleotide constructs based on beta-arabinofuranose and its analogues
CA2086105A1 (fr) Methode de traitement de la leucemie
Fujita et al. Discrimination of a single base change in a ribozyme using the gene for dihydrofolate reductase as a selective marker in Escherichia coli
Kumar et al. Point and compensation mutations to evaluate essential stem structures of genomic HDV ribozyme
PT2360253E (pt) Métodos de produção de células ou organismos knockdown através de interferência por rna com mediadores de rna específicos de sequência e usos dos mesmos
EP1232285A4 (fr) Arn catalytiques a activite d'aminoacylation
WO1999036517A3 (fr) Procede de selection de ribozymes capables de modifier par covalence les acides ribonucleiques, en trans, sur les groupes 2'-oh
EP1201751A1 (fr) Méthode pour la sélection d'acides nucléiques fonctionnels au sein de cellules

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA